CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 1,061,000
Costs and expenses:
Patient expenses			0	86,000
Selling, general and administrative	221,000	268,000	878,000	815,000
Total	221,000	268,000	878,000	901,000
Operating (loss) income	(221,000)	(268,000)	(878,000)	160,000
Total other (expense) income
Interest expense	0	0	0	(3,000)
Interest income - sales-type sublease			0	8,000
Other income	0	9,000	0	9,000
Loss from investments in unconsolidated entities, net	(156,000)	(77,000)	(1,287,000)	(351,000)
Total other expense	(156,000)	(68,000)	(1,287,000)	(337,000)
(Loss) income before income taxes	(377,000)	(336,000)	(2,165,000)	(177,000)
Provision for income taxes	(1,000)	(16,000)	(2,000)	(500,000)
Net loss	(378,000)	(352,000)	(2,167,000)	(677,000)
Net loss attributable to noncontrolling interests	57,000	0	325,000	0
Net loss attributable to U.S. Neurosurgical Holdings, Inc.	$ (321,000)	$ (352,000)	$ (1,842,000)	$ (677,000)
Basic net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.04)	$ (0.05)	$ (0.24)	$ (0.09)
Diluted net loss per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.04)	$ (0.05)	$ (0.24)	$ (0.09)
Weighted average common shares outstanding, basic (in shares)	7,792,185	7,792,185	7,792,185	7,792,185
Weighted average common shares outstanding, diluted (in shares)	7,792,185	7,792,185	7,792,185	7,792,185